GlassScriptPhysician profile
Patrick Arthur Newbury
NPI 1205490281
$1,037.80
in general payments reported to CMS, 2019-2025
20 companies · $615 in 2025
The $615 reported for 2025 was more than what 78% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $30.18 · 2023: $213 · 2024: $180 · 2025: $615.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,008.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,007.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Reflexion Medical, INC. | $213.00 | 2023 | Reflexion Medical Radiotherapy System |
| Novartis Pharmaceuticals Corporation | $153.01 | 2024-2025 | |
| Daiichi Sankyo INC. | $142.72 | 2024-2025 | Enhertu, Datroway |
| Regeneron Healthcare Solutions, INC. | $55.97 | 2024-2025 | Libtayo |
| Iovance Biotherapeutics, INC. | $45.43 | 2025 | Amtagvi |
| Takeda Pharmaceuticals U.S.A., INC. | $42.26 | 2024-2025 | Fruzaqla |
| Novocure INC. | $40.90 | 2025 | Optune Gio |
| Syndax Pharmaceuticals, INC. | $40.61 | 2025 | Revuforj |
| Genentech USA, INC. | $39.13 | 2025 | Polivy |
| Monteris Medical Corporation | $37.01 | 2024 | Neuroblate |
| Merck Sharp & Dohme LLC | $33.39 | 2025 | Reblozyl, Keytruda Qlex, Keytruda |
| Siemens Medical Solutions USA, INC. | $30.18 | 2022 | |
| Sobi, INC | $29.89 | 2025 | |
| Pfizer INC. | $27.91 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $22.40 | 2025 | Tagrisso |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bioprotect Medical, INC. | $22.39 | 2025 | Bioprotect Balloon Implant System |
| Medtronic, INC. | $18.12 | 2025 | Superlock |
| Lilly USA, LLC | $15.51 | 2025 | Verzenio, Jaypirca |
| Amgen INC. | $14.23 | 2025 | Blincyto |
| Tersera Therapeutics LLC | $13.74 | 2024 | Zoladex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Newbury listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.